Solabegron

Drug Profile

Solabegron

Alternative Names: 427353; GW-427353; GW-427353B

Latest Information Update: 24 Oct 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer AltheRx; Velicept Therapeutics
  • Class Aniline compounds; Antihyperglycaemics; Benzoic acids; Obesity therapies; Small molecules
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Irritable bowel syndrome; Overactive bladder
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 17 Oct 2016 Velicept Therapeutics initiates enrolment in the phase I trial for Overactive Bladder (In Volunteers) in USA (NCT02938507)
  • 05 Oct 2016 The US FDA approves IND application for solabegron once daily formulation in Overactive bladder
  • 05 Oct 2016 Velicept plans a phase I trial for Overactive bladder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top